hail
PepGen(NASDAQ: PEPGShares of the corporate plunged 25% in after-hours buying and selling on Tuesday after the corporate launched information on its drug PGN-EDO51 to deal with Duchenne muscular dystrophy (DMD).
PepGen reviews information from ongoing Part 2 5mg/kg dose arm The examine, CONNECT1-EDO51, famous that each one sufferers had elevated ranges of dystrophin, in keeping with a press release.
The biotech stated it expects to report preliminary outcomes from the ten mg/kg cohort in early 2025.
It added that it’s optimizing the design of its CONNECT2 Part 2 examine primarily based on information from CONNECT1, together with the drug’s rising security profile. The CONNECT2 examine is open within the UK and the corporate will proceed to work with EU regulators. PepGen stated it expects to launch the examine in the USA by the top of this 12 months.
The corporate held a convention name after the shut on Tuesday to debate the info.
Different corporations with DMD therapies available on the market or in improvement embody Sarepta (SRPT), Pfizer (PFE), Catalyst (CPRX), Edgewise Therapeutics (EWTX), Satellos (OTC:MSCLF), Entrada (TRDA), Dyne Therapeutics (DYN) ), Regenxbio (RGNX), Wave Life Sciences (WVE), Vertex Prescribed drugs (VRTX), Stable Biosciences (SLDB), Capricor (CAPR), Avidity (RNA) and Roche (OTCQX:RHHBY).
